Analysis of European Biosimilars Market

Huge Market Opportunity from Impending Patent Expiries of Blockbuster Biologics.
Share this:
     
Published: 20 Dec 2011

The aim of this research study is to thoroughly assess and analyse the biosimilars market, as well as market and technology trends in Europe, in order to provide strategic recommendations for the success of market participants. This study is focused on established segments in Europe including Erythropoietin, Granulocyte Colony Stimulating Factors, Human Growth Hormones and emerging segments including monoclonal antibodies, Insulin and interferon. The established market segments consist of products currently approved and marketed in Europe. New therapeutic classes of drugs are expected to be a major contributor in the emerging market segments.

  1.  
  2.  
  3.  
  4.  
  5.  
  6.  
  7.  

Tools

Features of this research

SUBSCRIPTIONS

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..